HemOnc today | APRIL 25, 2016 | Healio.com/HemOnc 57

Pancreatic Cancer Drugs in the Pipeline

HemOnc Today presents this guide to drugs in phase 2 or phase 3 development for pancreatic cancer. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. Generic name (Brand name, Manufacturer) Indication(s) Development status

ABT-888 (Abbott) combination treatment for metastatic disease phase 2 ACP-196 (Acerta Pharma) combination therapy for advanced or metastatic disease phase 2 aglatimagene besadenovec (Advantagene) nonmetastatic disease phase 2 algenpantucel-L (NewLink Genetics) borderline resectable or locally advanced unresectable disease; surgically phase 3 resected disease ALT-803 (Altor Bioscience Corporation) combination treatment for advanced disease phase 2 apatorsen (OncoGenex Pharmaceuticals) treatment-naive metastatic disease phase 2 BAX2398 (Baxalta) combination treatment phase 2 BC-819 (BioCancell Therapeutics) first-line treatment phase 2 BPM 31510 (Berg LLC) advanced disease phase 2 cabozantinib (Cometriq, Exelixis) advanced pancreatic neuroendocrine and carcinoid tumors phase 2 cancer macrobeads (Metromedia Bio-Science and Rogosin Institute) treatment-resistant disease phase 2 CPI-613 (Cornerstone Pharmaceuticals) combination treatment phase 2 CRS-207 (Aduro Biotech) combination treatment phase 2 dacomitinib (Pfizer) combination treatment for advanced KRAS-mutant disease phase 2 (OncoMed Pharmaceuticals) combination first-line treatment for metastatic disease phase 2 (NPC-1C, Precision Biologics) metastatic disease phase 2 evofosfamide (TH-302, EMD Serono and Threshold Pharmaceuticals) combination treatment for metastatic or locally advanced, unresectable disease phase 3 FG-3019 (Fibrogen) combination treatment for locally advanced, unresectable disease phase 2 galunisertib (Eli Lilly) pancreatic cancer phase 2 GI-4000 (GlobeImmune) resected disease phase 2 glufosfamide (Eleison Pharmaceuticals) second-line treatment for metastatic disease phase 3 GSK2256098 (GlaxoSmithKline) combination treatment for advanced disease phase 2 GVAX Pancreas (Aduro Biotech) surgically resectable disease phase 2 ibrutinib (Imbruvica, Janssen and Pharmacyclics) advanced carcinoid and pancreatic neuroendocrine tumors phase 2 INCB039110 (Incyte) combination treatment for advanced disease phase 2 (Yervoy, Bristol-Myers Squibb) combination treatment for metastatic disease phase 2 Kanglaite injection (KangLaiTe USA) pancreatic cancer phase 2 masitinib (AB Science USA) combination treatment for advanced or metastatic disease phase 3 MM-141 (Merrimack Pharmaceuticals) combination treatment for frontline metastatic disease phase 2 MM-398 (Onivyde, Baxalta and Merrimack Pharmaceuticals) first-line treatment phase 2 momelotinib (Gilead Sciences) combination treatment for treatment-naive, metastatic disease phase 3 necuparanib (M402, Momenta Pharmaceuticals) combination treatment for metastatic disease phase 2 (Biotech Pharma) combination treatment for KRAS wild-type locally advanced or metastatic disease phase 2 NPC-1C (Precision Biologics) combination treatment phase 2 olaparib (Lynparza, AstraZeneca) BRCA–positive disease; metastatic disease phase 2

BRCA–mutated disease that has not progressed on first-line platinum-based phase 3 oregovomab (Quest PharmaTech) combination treatment for locally advanced disease phase 2 paclitaxel protein-bound particles for injectable suspension adjuvant therapy phase 3 [albumin-bound] (Abraxane, Celgene) pazopanib (Votrient, Novartis) advanced pancreatic neuroendocrine tumors phase 2 PBI-05024 (Phoenix Biotechnology) stage IV metastatic disease phase 2 PEGPH20 (Halozyme Therapeutics) combination treatment for stage IV untreated disease; combination phase 2 treatment for newly diagnosed metastatic disease pelareorep (Reolysin, Oncolytics Biotech) combination treatment for advanced or metastatic disease phase 2 (Keytruda, Merck) resectable or borderline resectable disease phase 2 polyclonal antibody stimulator (G17DT, Cancer Advances Inc.) metastatic disease phase 3 regorafenib (Stivarga, Bayer) advanced disease phase 2 rucaparib (Clovis Oncology) pancreatic cancer with known deleterious BRCA mutation phase 2 ruxolitinib (Jakafi, Incyte) combination treatment for advanced or metastatic disease phase 3 SGT-53 (SynerGene Therapeutics) combination treatment for metastatic disease phase 2 sulfatinib (Hutchison Medipharma) advanced pancreatic neuroendocrine tumors phase 3 (OncoMed Pharmaceuticals) combination treatment for previously untreated stage IV disease phase 2 TL-118 (Tiltan Pharma) pancreatic cancer previously treated with gemcitabine phase 2 trametinib (Mekinist, Novartis) combination treatment for advanced disease phase 2 X-82 (Tyrogenex) pancreatic neuroendocrine tumors phase 2

Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HemOnc Today. The publisher or editors do not assume responsibility for any errors or omissions.